We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mutation Reducing Fatty Acid-Binding Protein Activity Lowers Heart Attack Risk

By LabMedica International staff writers
Posted on 08 Sep 2014
Print article
Image: Illustration comparing a normal blood vessel and partially blocked vessel due to atherosclerotic plaque build-up (Photo courtesy of Wikimedia Commons).
Image: Illustration comparing a normal blood vessel and partially blocked vessel due to atherosclerotic plaque build-up (Photo courtesy of Wikimedia Commons).
A team of Finnish cardiovascular disease researchers found that a mutation generating a low-expression variant of fatty acid-binding protein 4 (FABP4), reduced the risk of heart attack and stroke.

The FABP4 gene encodes the fatty acid binding protein found in adipocytes. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. It is thought that the roles of FABPs include fatty acid uptake, transport, and metabolism. Earlier studies detected a mutation (rs77878271) in the human FABP4 gene that caused reduced FABP4 protein transcription.

Investigators at the University of Helsinki (Finland) examined the effects of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis in a random group of 7,491 individuals and in patient cohorts. The cohorts consisted of patients with advanced carotid atherosclerosis who had undergone surgical procedures (endarterectomy) to excise the inner lining of arteries clogged with atherosclerotic buildup (n = 92) and those having experienced myocardial infarction (MI, n = 3,432).

Results published in the August 13, 2014, online edition of the journal Circulation: Cardiovascular Genetics revealed that the low-expression variant was associated with decreased total cholesterol levels with the largest reduction being in individuals carrying two alleles for the variant. Obese variant allele carriers also showed reduced carotid intima-media thickness and lower prevalence of carotid plaques. Consistently, the variant allele homozygotes showed eight-fold lower odds for MI.

The variant allele was associated with a 3.8-fold reduction in FABP4 transcription and 2.7-fold reduction in apoptosis in the macrophages associated with carotid plaques. High FABP4 expression in carotid plaques was associated with lipid accumulation, intraplaque hemorrhages, plaque ulcerations and phosphoactivated ER (endoplasmic reticulum) stress markers.

"It could be that reduced cell stress in the stenosis, attenuated inflammation, as well as reduced accumulation of cholesterol and other lipids in the arteries help keep atherosclerosis asymptomatic among the gene carriers," said first author Dr. Jani Saksi, a researcher in molecular neurology at the University of Helsinki. "These findings suggest that FABP4 could be a new potential target for drug development aiming to prevent lethal and disabling myocardial and cerebral infarctions induced by atherosclerosis. The inhibition of FABP4 activity – especially among obese people in the risk group for atherosclerosis – may prove to be an important method for reducing these individuals' risk for cardiovascular diseases."

Related Links:

University of Helsinki


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.